SOUTH SAN FRANCISCO, Calif., May 18, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced that its chief executive officer, Ted W. Love, M.D. will present a corporate update at the UBS 2016 Global Healthcare Conference on Tuesday, May 24 at 1:30 p.m. Eastern Time.
The presentation will be webcast live and available for replay from GBT's website at www.globalbloodtx.com in the Investors section.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is currently evaluating GBT440 in both healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind Phase 1/2 clinical trial. In addition to GBT440 for the treatment of SCD, GBT is engaged in research and development activities targeted toward hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis (IPF) and hereditary angioedema (HAE). To learn more, please visit: www.globalbloodtx.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-blood-therapeutics-to-present-at-the-ubs-2016-global-healthcare-conference-300271032.html
SOURCE Global Blood Therapeutics, Inc.
Myesha Edwards, Global Blood Therapeutics, 650-351-4730, email@example.com